TY  - JOUR
PY  - 2011//
TI  - Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran
JO  - American journal of therapeutics
A1  - Baghaei, Parvaneh
A1  - Tabarsi, Payam
A1  - Dorriz, Donna
A1  - Marjani, Majid
A1  - Shamaei, Masoud
A1  - Pooramiri, Majid Valiollah
A1  - Mansouri, Davood
A1  - Farnia, Parisa
A1  - Masjedi, Mohammadreza
A1  - Velayati, Aliakbar
SP  - e29
EP  - 34
VL  - 18
IS  - 2
N2  - Compared with the treatment of drug-sensitive tuberculosis, the treatment of multidrug-resistant tuberculosis (MDR-TB) is more difficult. This study was conducted at the national referral center of tuberculosis in Tehran, Iran, to evaluate adverse drug reactions of treatment of MDR-TB. From 2006 to 2009, all patients admitted into Masih Daneshvari Hospital in Tehran, Iran, for MDR-TB were considered for this study. The standard treatment for MDR-TB consisted of amikacin, prothionamide, ofloxacin, and cycloserine. Ethambutol and pyrazinamide were added to treatment if mycobacterium was sensitive to them. All adverse effects observed in patients were recorded in our registry. Eighty patients were considered in the study; of this cohort, 44 were male and 36 were female. The mean age of patients was 40.64 ± 17.53 years (range, 14-81 years). All patients received standardized therapy for MDR-TB. The major adverse effects included neurologic side effects (depression, convulsions, consciousness, psychosis, suicide; 7.5%), hepatitis (5%), rash (1.3%), renal toxicity (3.8%), and auditory toxicity (14.5%). Those with neurologic side effects had less favorable outcome (P value = 0.038) and risk of death was increased among them (odds ratio, 13.8; 95% confidence interval, 2.2-86.77). Other adverse effects did not show statistical significance in our analysis. A major adverse effect such as neurologic side effects (depression, convulsions, consciousness, and psychosis) can result in an increased chance of death among patients with MDR-TB.<p /> <p>Language: en</p>
LA  - en
SN  - 1075-2765
UR  - http://dx.doi.org/10.1097/MJT.0b013e3181c0806d
ID  - ref1
ER  -